Core Insights - The company expects to complete conditional Marketing Authorization Application submissions to the U.K. and European regulatory agencies by the end of Q1 2026 [1] - Additional biomarker data from the Human Metastatic Osteosarcoma Program is set to be released in Q1 2026, which aims to support the use of biomarkers as surrogate endpoints for clinical efficacy [2] - The company acquired listeria-based assets from Ayala Pharmaceuticals in April 2025, and Ayala has since liquidated its shares in the company [3] Technical Analysis - The stock is currently trading 8.0% below its 20-day simple moving average and 15.0% below its 100-day simple moving average, indicating short-term weakness [4] - Over the past 12 months, shares have decreased by 38.07%, reflecting ongoing challenges for the company [4] - The RSI is at a neutral level, and MACD is also neutral, suggesting mixed momentum for the stock [5] Analyst Consensus & Recent Actions - The stock carries a Buy Rating with an average price target of $18.25, with recent analyst moves maintaining a target of $20 [6] - OS Therapies shares were up 2.46% at $1.25 during premarket trading [6] - Key resistance is identified at $1.50 and key support at $1.12 [6]